Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | USP14 | P54578 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547360 | 0.95 | KCNA3 (0.52) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL31037283 | 0.92 | CTSK (0.56) | KCNA3CTSKDRD2CCR5BTK | |
| SCHEMBL9092293 | 0.92 | KCNA3 (0.54) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL30893341 | 0.90 | KCNA3 (0.53) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26813917 | 0.89 | KCNA3 (0.52) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26814319 | 0.89 | KCNA3 (0.52) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL3108831 | 0.88 | KCNA3 (0.56) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26813889 | 0.87 | KCNA3 (0.50) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL12971748 | 0.87 | KCNA3 (0.57) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26665267 | 0.87 | KCNA3 (0.57) | KCNA3CTSKDRD2CCR5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2025-07-29 | — | — | US | disclosed |
| EP-4558137-A2 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025105486-A1 | ANTIBODY-PHOTOSENSITIVE SUBSTANCE CONJUGATE | 第一三共株式会社 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025076501-A1 | HIGH THROUGHPUT PARALLEL SYNTHESIS OF SMALL MOLECULE DEGRADERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250019376-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | US | disclosed |
| WO-2024210572-A1 | NOVEL IMIDAZOLE DERIVATIVE AND USE THEREOF | 주식회사 펠레메드 | 2024-10-10 | — | — | WO | disclosed |
| EP-4433476-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | Merck Sharp & Dohme LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-11932637-B2 | Chromane amidine monobactam compounds for the treatment of bacterial infections | MERCK SHARP & DOHME LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20210188855-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-06-24 | — | — | US | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2019-10-17 | — | — | US | disclosed |
| CN-110214141-A | Benzodiazole compound as ENaC inhibitor | 企业治疗学有限公司 | 2019-09-06 | — | — | CN | disclosed |
| US-6627651-B1 | Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| EP-1182195-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315757-A1 | BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS | NHERF1, SCNN1B, SCNN1A | KCNA3 86/4885CTSK 3416/4885DRD2 3893/4885 |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | KCNA3 3648/4885CTSK 2003/4885DRD2 4879/4885 |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | KCNA3 64/4885CTSK 3834/4885DRD2 3943/4885 |
| US-20250019376-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | PAM, ACMSD, MGAM2 | KCNA3 2046/4885CTSK 1418/4885DRD2 3707/4885 |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | SCNN1B, SCNN1A, SCNN1G | KCNA3 71/4885CTSK 3001/4885DRD2 4278/4885 |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | KCNA3 86/4885CTSK 3416/4885DRD2 3893/4885 |
| US-20210188855-A1 | COMPOUNDS | NHERF1, SCNN1B, SCNN1A | KCNA3 99/4885CTSK 3669/4885DRD2 4100/4885 |
| US-11932637-B2 | Chromane amidine monobactam compounds for the treatment of bacterial infections | MGAM, MGAM2, ELANE | KCNA3 2412/4885CTSK 1526/4885DRD2 4727/4885 |
| US-10941149-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | KCNA3 64/4885CTSK 3834/4885DRD2 3943/4885 |
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | KCNA3 86/4885CTSK 3416/4885DRD2 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.